Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

WGBS of control and DAC-treated tumor tissue from PDX model

ABSTRACT: WGBS of control and DAC-treated tumor tissue from PDX model

PROVIDER: PRJNA793430 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17395459_1.fastq.gz	Fastqsanger.gz
	SRR17395459_2.fastq.gz	Fastqsanger.gz
	SRR17395460_1.fastq.gz	Fastqsanger.gz
	SRR17395460_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

DAC-treated tumor tissue from PDX model and DAC-treated CT26 cells.

Project description:DAC-treated tumor tissue from PDX model and DAC-treated CT26 cells.

| PRJNA793007 | ENA

RNA sequencing of control and DAC-treated tumor tissue from PDX model

Project description:RNA sequencing of control and DAC-treated tumor tissue from PDX model

| PRJNA793011 | ENA

WGBS of control and DAC-treated tumor tissue from PDX model

Project description:PD-1 blockade has demonstrated impressive clinical outcomes in colorectal cancers that have high microsatellite instability. However, the therapeutic efficacy for patients with tumors with low microsatellite instability or stable microsatellites needs further improvement. Here, we have demonstrated that low-dose decitabine could increase the expression of immune-related genes such as major histocompatibility complex genes and cytokine-related genes as well as the number of lymphocytes at the tumor site in CT26 colorectal cancer-bearing mice. A more significant inhibition of tumor growth and a prolongation of survival were observed in the CT26 mouse model after treatment with a combination of PD-1 blockade and decitabine than in mice treated with decitabine or PD-1 blockade alone. The anti-tumor effect of the PD-1 blockade was enhanced by low-dose decitabine. The results of RNA sequencing and whole-genome bisulfite sequencing of decitabine-treated CT26 cells and tumor samples with microsatellite stability from the patient tumor-derived xenograft model have shown that many immune-related genes, including antigen processing and antigen-presenting genes, were upregulated, whereas the promoter demethylation was downregulated after decitabine exposure. Therefore, decitabine-based tumor microenvironment re-modulation could improve the effect of the PD-1 blockade. The application of decitabine in PD-1 blockade-based immunotherapy may elicit more potent immune responses, which can provide clinical benefits to the colorectal cancer patients with low microsatellite instability or stable microsatellites.

2022-01-03 | GSE192833 | GEO

WGBS of control and DAC-treated CT26 cells.

Project description:WGBS of control and DAC-treated CT26 cells.

| PRJNA793429 | ENA

DAC-treated tumor tissue from PDX model and DAC-treated CT26 cells.

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-01-03 | GSE192745 | GEO

RNA sequencing of control and DAC-treated tumor tissue from PDX model

2022-01-03 | GSE192743 | GEO

Melanoma progression model:DAC-mediated gene expression

Project description:Melanoma progression model:DAC-mediated gene expression Keywords: other

2005-07-20 | GSE1793 | GEO

Dexamethasone-resistant multiple myeloma cell line OPM1 treated with Dexamethasone and/or DAC

Project description:To identify genes responsible for the synergistic effect of DAC with Dex, we performed cDNA microarray analyses using cDNA prepared from Dex-resistant OPM1 cells treated with/without Dex, DAC or DAC+Dex.

2009-01-03 | GSE14261 | GEO

Tissue proteome data of mouse PDX model

Project description:The proteome of mouse PDX model was combined with exosomal proteome to explore the feasibility of exosomal characterization of tumor status

2023-07-03 | PXD043517 |

Expression profiling of DLBCL subtypes PDX model

Project description:Identify the PDX model of DLBCL subtypes by the microarray expression profiling Four samples without relplicates

2016-02-29 | E-GEOD-65988 | biostudies-arrayexpress